Tøndell Anders, Subbannayya Yashwanth, Wahl Sissel Gyrid Freim, Flatberg Arnar, Sørhaug Sveinung, Børset Magne, Haug Markus
Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Cancers (Basel). 2021 Apr 9;13(8):1788. doi: 10.3390/cancers13081788.
Non-small cell lung carcinoma (NSCLC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths. Immunotherapy with immune checkpoint inhibitors shows beneficial responses, but only in a proportion of patients. To improve immunotherapy in NSCLC, we need to map the immune checkpoints that contribute immunosuppression in NSCLC-associated immune cells and to identify novel pathways that regulate immunosuppression. Here, we investigated the gene expression profiles of intra-tumoral immune cells isolated from NSCLC patients and compared them to the expression profiles of their counterparts in adjacent healthy tissue. Transcriptome analysis was performed on macrophages, CD4 and CD8 T cells. The data was subjected to Gene Ontology (GO) term enrichment and weighted correlation network analysis in order to identify mediators of immunosuppression in the tumor microenvironment in NSCLC. Immune cells from NSCLC revealed a consistent differential expression of genes involved in interactions between myeloid cells and lymphocytes. We further identified several immunosuppressive molecules and pathways that may be activated in tumor-associated macrophages in NSCLC. Importantly, we report novel data on immune cell expression of the newly described CD200/CD200R1 pathway, and the leukocyte immunoglobulin-like receptors (LILRs), which may represent novel innate immune checkpoints, dampening the anti-tumor T cell immune response in NSCLC. Our study substantiates the importance of tumor-associated macrophages as a mediator of immunosuppression and a promising target for immunotherapy.
非小细胞肺癌(NSCLC)是最常被诊断出的癌症之一,也是癌症相关死亡的主要原因。使用免疫检查点抑制剂进行免疫治疗显示出有益的反应,但仅在一部分患者中有效。为了改善NSCLC的免疫治疗,我们需要绘制在NSCLC相关免疫细胞中导致免疫抑制的免疫检查点,并识别调节免疫抑制的新途径。在此,我们研究了从NSCLC患者分离的肿瘤内免疫细胞的基因表达谱,并将其与相邻健康组织中对应细胞的表达谱进行比较。对巨噬细胞、CD4和CD8 T细胞进行了转录组分析。对数据进行基因本体(GO)术语富集和加权相关网络分析,以识别NSCLC肿瘤微环境中免疫抑制的介质。来自NSCLC的免疫细胞显示出参与髓样细胞与淋巴细胞相互作用的基因存在一致的差异表达。我们进一步鉴定了几种可能在NSCLC肿瘤相关巨噬细胞中被激活的免疫抑制分子和途径。重要的是,我们报告了新描述的CD200/CD200R1途径以及白细胞免疫球蛋白样受体(LILR)在免疫细胞表达方面的新数据,它们可能代表新的固有免疫检查点,抑制NSCLC中的抗肿瘤T细胞免疫反应。我们的研究证实了肿瘤相关巨噬细胞作为免疫抑制介质和免疫治疗有前景靶点的重要性。